Clinical Trials
19 trialsNCT07410117 2026-05-27
ROXI-CAT-I
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT05171075 2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3 Terminated
NCT07493304 2026-03-25
ROXI-CAT-II
Regeneron Pharmaceuticals
Phase 3 Not yet recruiting
NCT05171049 2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3 Terminated
NCT06861088 2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3 Recruiting
NCT04649489 2026-01-15
TALENTOP
Fudan University
Phase 3 Active not recruiting
NCT03080883 2025-05-18
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Academic and Community Cancer Research United
Phase 3 Completed
NCT06149533 2023-11-29
Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Not yet recruiting
NCT02585713 2020-08-04
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
Phase 3 Completed
NCT04462003 2020-07-08
DVT
Beni-Suef University
Phase 3 Unknown
NCT04309240 2020-03-16
Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports
LiuZhou People's Hospital
Phase 3 Unknown
NCT03240120 2019-04-17
A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
The University of Hong Kong
Phase 3 Unknown
NCT02073682 2019-03-06
Cancer Venous Thromboembolism (VTE)
Daiichi Sankyo
Phase 3 Completed
NCT03740633 2018-11-14
Functional Training for the Prevention of Deep Venous Thrombosis
Peking Union Medical College Hospital
Phase 3 Unknown
NCT00539942 2017-03-27
Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy
University of Alabama at Birmingham
Phase 3 Terminated
NCT00312013 2017-03-23
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
GlaxoSmithKline
Phase 3 Completed
NCT01164046 2014-12-03
Longheva
University Medical Center Groningen
Phase 3 Terminated
NCT00219973 2010-04-28
CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)
Rovi Pharmaceuticals Laboratories
Phase 3 Completed
NCT00135876 2007-04-27
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
Ontario Clinical Oncology Group (OCOG)
Phase 3 Completed